Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
adalimumab (humira) (1 trial)
infliximab (remicade) (1 trial)
risankizumab (Skyrizi) (1 trial)
ustekinumab (stelara) (1 trial)
vedolizumab (entyvio) (1 trial)
mesalamine (rowasa) (2 trials)
mesalazine (1 trial)
naltrexone (revia) (1 trial)
avb-114 (1 trial)
cellulose (1 trial)
levocarnitine (carnitor) (1 trial)
polyethylene glycol (1 trial)
Faecalibacterium prausnitzii (1 trial)
Atherosclerosis (Phase 2)
Colitis (Phase 3)
Colitis, Ulcerative (Phase 3)
Crohn Disease (Phase 3)
Metabolic Syndrome (Phase 2)
Syndrome (Phase 2)
Ulcer (Phase 3)
Trials (8 total)
Trial APIs (13 total)